# US 8,465,918 B2 · Ultraconserved regions encoding ncRNAs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,465,918 B2
- Document ID: US8465918B2
- Status: Granted
- Kind: B2
- Application number: 12/672,014
- Filed: 2008-08-04
- Published: 2010-07-22
- Granted: 2013-06-18
- Earliest claimed: 2007-08-03
- Assignees: The Ohio State University Research Foundation
- Applicants: Carlo M. Croce
- Inventors: Carlo M. Croce
- Web page: https://patentgrep.com/patent/US8465918B2

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2320/10: in screening processes
- C12N 2320/11: for the determination of target sites, i.e. of active nucleic acids
- C12N 2330/10: naturally occurring
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described herein are methods for differentiate human cancers comprising using one or more transcribed ultraconserved regions (T-UCR) expression profiles where the association between the genomic location of UCRs and the analyzed cancer-related genomic elements is highly statistically significant and comparable to that reported for miRNAs.

## Claims

### Claim 1

A method to identify a relative risk in a vertebrate for developing chronic lymphocytic leukemia, comprising:
(a) obtaining a nucleic acid-containing test sample from a vertebrate subject,
(b) measuring, by laboratory analysis, a level of at least one transcribed ultra-conserved regions (T-UCR),
(c) identifying whether the test sample expresses at least one T-UCR,
(d) determining the relative risk for developing chronic lymphocytic leukemia by comparing the at least one T-UCR measured level to the level of a corresponding T-UCR in a control sample,
wherein a decrease in the level of at least one T-UCR in the test sample, relative to the level of a corresponding T-UCR in a control sample, is indicative of the subject either having, or being at risk for developing chronic lymphocytic leukemia, wherein the at least one T-UCR is uc.160(N), and
(e) measuring the level of at least one miR-155 in the test sample from said subject,
wherein an increase in the level of the miR-155 in the test sample, relative to the level of a corresponding miR-155 in a control sample, is indicative of the subject either having, or being at risk for developing chronic lymphocytic leukemia.

### Claim 2 (depends on 1)

The method of claim 1, further comprising measuring one or more additional T-URCs selected from: uc.269A(N) and uc.346A(P).

### Claim 3 (depends on 1)

The method of claim 1, further comprising measuring at least one additional T-UCR selected from uc.215(N) and uc.348(N).